Verve Therapeutics, Inc. - Common Stock (VERV)

The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future.

VERV stock results show that Verve Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides.

There are a few silver linings at play here.

On Monday, Cathie Wood-led Ark Invest made some significant trades, with Coinbase Global Inc. (NASDAQ:COIN) taking the spotlight. This comes amidst a turbulent market scenario, particularly for cryptocurrencies. The COIN Trade

Ark Invest, led by Cathie Wood, made significant trades on Wednesday involving Robinhood Markets Inc (NASDAQ:HOOD) and Zoom Video Communications Inc (NASDAQ:ZM).

On Monday, Cathie Wood-led Ark Invest made a significant move by reducing its holdings in Robinhood Markets Inc (NASDAQ:HOOD). This decision came amidst a period of market fluctuations and followed a recent trend of the investment firm adjusting its portfolio.

Cathie Wood's flagship ARK Innovation ETF has been navigating through significant losses, showcasing the challenges faced by some of its major holdings.

Discover three biotech stocks handpicked by Cathie Wood, offering groundbreaking therapies and substantial growth potential.

10x stocks are the holy grail of capital investing. So, here are three companies that have the potential to cross that line.

VERV stock results show that Verve Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

On Thursday, Cathie Wood-led Ark Invest made a significant move by selling shares of Coinbase Global Inc (NASDAQ:COIN), despite the stock’s positive market performance on the same day. The COIN Trade

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dipping over 1% on Tuesday. The Dow traded down 1.07% to 39,142.53 while the NASDAQ fell 1.14% to 16,209.12. The S&P 500 also fell, dropping, 0.85% to 5,199.28.

Stocks are starting the second quarter off on the wrong foot, as profit taking grips Wall Street.

Shares of Stryve Foods, Inc. (NASDAQ: SNAX) fell sharply during Tuesday’s session following a fourth-quarter revenue miss.

Verve Therapeutics' latest update on the Heart-1 Phase 1b trial of VERVE-101. Explore VERVE-102's development and regulatory clearances for the Heart-2 clinical trial, offering hope for patients with cardiovascular conditions.

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Tuesday. The Dow traded down 1.05% to 39,152.47 while the NASDAQ fell 1.17% to 16,205.37. The S&P 500 also fell, dropping, 0.89% to 5,196.96.